What is Silo Pharma?
Silo Pharma Inc. operates as a developmental stage biopharmaceutical entity dedicated to addressing critical gaps in mental health and chronic pain management. The company specializes in the synthesis of conventional pharmaceutical agents and innovative psychedelic formulations designed to treat PTSD, stress-induced psychiatric disorders, and various central nervous system diseases. By targeting these underserved therapeutic areas, Silo Pharma occupies a high-growth niche within the broader biotechnology market, leveraging scientific rigor to transform patient outcomes in psychiatric care.
How much funding has Silo Pharma raised?
Silo Pharma has raised a total of $8.3M across 2 funding rounds:
Share Placement
$4.3M
Stock/Share Issuance
$4M
Share Placement (2021): $4.3M, investors not publicly disclosed
Stock/Share Issuance (2026): $4M, investors not publicly disclosed
Key Investors in Silo Pharma
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for Silo Pharma?
With the recent influx of capital, Silo Pharma is expected to prioritize the advancement of its clinical trial programs and the expansion of its intellectual property portfolio. The strategic allocation of these funds will likely focus on scaling manufacturing capabilities for its proprietary formulations and deepening its research into the efficacy of psychedelic-assisted therapies. As the company transitions through its current lifecycle stage, stakeholders will be monitoring the progression of its lead candidates through regulatory milestones, which remain the primary catalysts for long-term value creation in the biopharma space. The firm's ability to maintain its research momentum while navigating the evolving legal frameworks surrounding psychedelic medicine will be a key determinant of its future market performance.
See full Silo Pharma company page
